Interview with the Innovators
Supported byAsk the Experts

Closely Monitoring of Regorafenib-Related Side Effects: When and Why

Videos
Tanios S. Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer,
Mayo Clinic Cancer Center Consultant
Mayo Clinic, Phoenix, AZ
Daniel Ahn, DO, MS
Assistant Professor of Medicine
Mayo Clinic, AZ
Dr. Bekaii-Saab and Dr. Ahn offer the rationale for a practical monitoring schedule for patients treated with Regorafenib.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: